Author

Jake J. Chabon

Observed names: J. J. Chabon, Jake Chabon

Observed institutions: Stanford Medicine, University of Colorado Denver, Stanford University

OpenAlex ID: A5031495533

Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC).

2024 · James M. Isbell, Jordan Scott Goldstein, et al. · Journal of Clinical Oncology · 15

End-of-Treatment Response Assessment after Frontline Therapy for Aggressive B-Cell Lymphoma: Landmark Comparison of a Singular PET/CT Scan Versus Ultrasensitive Circulating Tumor DNA

2023 · Mark Roschewski, Liza Lindenberg, et al. · Blood · 10

Development and Validation of Biopsy-Free Genotyping for Molecular Subtyping of Diffuse Large B-Cell Lymphoma

2016 · Florian Scherer, David M. Kurtz, et al. · Blood · 10

Polatuzumab vedotin with dose-adjusted etoposide, cyclophosphamide, doxorubicin, and rituximab (Pola-DA-EPCH-R) for upfront treatment of aggressive B-cell non-Hodgkin lymphomas.

2022 · Ryan C Lynch, Christina Poh, et al. · Journal of Clinical Oncology · 2

Abstract P2-01-25: Circulating tumor DNA clearance by neoadjuvant chemotherapy or breast surgery detected using an ultrasensitive ctDNA MRD assay in early breast cancer

2025 · Luc Cabel, Julia Ah-Reum An, et al. · Clinical Cancer Research

Abstract B49: Quantitating circulating tumor DNA in translocation-positive sarcoma patients using CAPP-Seq

2018 · Avanthi Tayi Shah, Tej D. Azad, et al. · Cancer Research

Works count: 7

Citation count: 47

H-index: 4

I10-index: 4